Home › Calculator › USRM Dividend Calculator 2026
USRM Dividend DRIP Calculator 2026
2000000.00% YieldHealthcareU.S. Stem Cell, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When USRM pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your USRM snowball 📈
$10,000 in USRM → $3.603059672953261e+54M in 10 years · $300,254,958,085,218,450,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/month
About U.S. Stem Cell, Inc. (USRM) — Dividend Analysis 2026
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
Compare USRM with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full USRM DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open USRM position with:
🌍 USRM Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold USRM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1600000.00% | 1599997.20% | $160,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1825000.00% | 1824997.20% | $182,500,000 / yr |
| 🇨🇦 TFSA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 1500000.00% | 1499997.20% | $150,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1472500.00% | 1472497.20% | $147,250,000 / yr |
| 🇫🇷 FR Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 USRM Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 USRM Dividend Payment Schedule
USRM pays quarterly — 4 times per year. Next ex-div: TBD.
📊 USRM vs Healthcare Benchmarks
How USRM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for USRM sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ USRM Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2022-04-25 | 2,500,000 | $0.00 | $10.0K | ||
| A-Award | 2022-03-18 | 25,000,000 | $0.01 | $200.0K | ||
| A-Award | 2022-02-24 | 12,500,000 | $0.01 | $100.0K | ||
| A-Award | 2022-02-24 | 12,500,000 | $0.01 | $100.0K | ||
| A-Award | 2021-03-23 | 7,518,797 | $0.03 | $200.0K | ||
| J-Other | 2021-04-02 | 187,575 | $0.05 | $9.1K | ||
| J-Other | 2020-10-05 | 2,035,820 | $0.00 | $9.2K | ||
| J-Other | 2020-04-01 | 1,445,647 | $0.01 | $8.7K | ||
| A-Award | 2021-02-17 | 3,759,398 | $0.03 | $100.0K | ||
| A-Award | 2019-11-18 | 1,500,000 | $0.00 | $7.3K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the USRM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
U.S. Stem Cell, Inc. (USRM) is currently trading at $0.00, 100% below its 52-week high. The current dividend yield is 2000000.00% based on an annual payout of $2.00 per share.
USRM (U.S. Stem Cell, Inc.) — 2000000.00% Dividend Yield Analysis
U.S. Stem Cell, Inc. (USRM) is a healthcare stock currently trading at $0.00 with a dividend yield of 2000000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (2000000.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.